Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
MetLife stock has delivered a strong 78.2% return over the past five years, yet its valuation signals are split, with the Excess Returns intrinsic value estimate pointing to meaningful upside while earnings based multiples suggest the shares trade on the expensive side.
A 78.2% gain over five years highlights that holding MetLife has been rewarding, which naturally raises the bar for what counts as good value today.
Expectations for steady insurance earnings and capital returns can support the intrinsic value case, while exposure to underwriting pressures and interest rate shifts may weigh on how much investors are willing to pay for those cash flows.
On Simply Wall St’s broader checklist, MetLife screens as undervalued on only 2 of 6 valuation tests, which leans more toward a stock that is not a straightforward bargain.
The issue now is whether MetLife’s current price more closely reflects the intrinsic value suggested by the Excess Returns model or the richer picture implied by traditional market multiples.
The Excess Returns model evaluates how much profit MetLife can generate on its equity above its own cost of capital. For MetLife, the inputs indicate a company that is expected to earn more on its book value than it is assumed to pay for that equity, which contributes to a higher intrinsic value estimate.
MetLife is modeled with book value of $42.30 per share rising toward a stable book value of $52.72 per share, while stable EPS of $8.48 per share is based on return on equity forecasts from 8 analysts. Against a cost of equity of $3.93 per share, the model implies excess return of $4.55 per share and an average return on equity of 16.09%. Using these inputs in the Excess Returns framework produces an intrinsic value estimate of $168.74 per share, which sits above the current share price, so the stock screens as undervalued on this basis.
On the Excess Returns model, MetLife appears undervalued, with the share price sitting below the estimated $168.74 intrinsic value.
For a mature insurer like MetLife, the P/E ratio is a straightforward way to check what the market is paying for each dollar of earnings. MetLife currently trades on a P/E of 16.9x, compared with the Insurance industry average of about 12.4x and a peer average of 14.7x, so investors are paying a higher multiple than for many other insurers.
The fair P/E ratio implied by Simply Wall St’s model is 14.4x, which reflects what might be reasonable given MetLife’s sector, size and risk profile. Against that benchmark, the stock trades at a premium of a little over 2 turns of earnings, which points to the market assigning a richer valuation than the model suggests is justified.
On this P/E measure, MetLife stock screens as overvalued relative to both its tailored fair ratio and typical insurance peers.
The MetLife Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives pick up where this MetLife valuation puzzle leaves off by spelling out which paths for MetLife’s future growth, margins and earnings would need to play out for the stock to be worth significantly more or less than today’s price. These Narratives sit on the company’s Community page. Each one ties a fair value to a clear storyline about potential catalysts and risks, so you can track over time which version of events appears to be unfolding.
If you have a clear, number driven view on where MetLife’s growth, margins and execution go from here, share a Narrative with the Simply Wall St community and set out the case in your own words. You can then track how your thesis on MetLife holds up as new results and information come through.
MetLife looks pulled between an intrinsic value framework that flags the stock as undervalued and market multiples that suggest it is already priced at a premium to peers. The intrinsic value estimate leans on MetLife’s ability to earn comfortably above its cost of equity, while the P/E view reflects what investors are currently willing to pay for those earnings. Broader valuation checks are weak, so that single intrinsic value signal needs to be weighed carefully. The key question from here is whether MetLife’s returns on equity and earnings quality stay strong enough for the market to keep supporting, or potentially expanding, that richer multiple.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
